T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor signaling. Recent analyses have shown that patients with CRC with mutated KRAS and BRAF oncogenes do not profit from treatment with such antibodies. Here we have used the binding domains of cetuximab and pantitumumab for constructing T cell-engaging BiTE antibodies. Both EGFR-specific BiTE antibodies mediated potent redirected lysis of KRAS- and BRAF-mutated CRC lines by human T cells at subpicomolar concentrations. The cetuximab-based BiTE antibody also prevented at very low doses growth of tumors from KRAS- and BRAF-mutated human CRC xenografts, whereas cetuximab was not effective. In nonhuman primates, no significant adverse events were observed during treatment for 3 wk at BiTE serum concentrations inducing, within 1 d, complete lysis of EGFR-overexpressing cancer cells. EGFR-specific BiTE antibodies may have potential to treat CRC that does not respond to conventional antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, EGFR-specific BiTEs were shown to lyse KRAS- and BRAF-mutated CRC cell lines in vitro and inhibit the growth of CRC xenograft tumors, while cetuximab was ineffective [188].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [188]
In the citing paper
“T cell-engaging BiTE antibodies targeting the binding domains of cetuximab and panitumumab transiently connect T cells with cancer cells to initiate redirected target cell lysis.”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [54]
In the citing paper
“Neither cetuximab nor panitumumab can engage T cells when T cells lack Fcγ receptors, which serve as targets for modifying T cells to enhance the ADCC activity of anti-EGFR agents [54].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [54]
In the citing paper
“showed that cetuximab-based BiTE antibody mediated potent redirected lysis of KRAS- and BRAF-mutated CRC lines in vitro and prevented the growth of tumours from xenografts [54].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [54]
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 3×
“These two dose levels were equivalent to, or even higher than, those of the anti-CD19 BiTE antibody blinatumomab, which led to a high rate of partial and complete tumor responses in patients with lymphoma (10) and led to molecular remissions in B-ALL patients.”
BackgroundMethodResultSelf-citationBispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“BiTE antibodies are designed to transiently connect T cells with cancer cells for initiation of redirected target cell lysis (5).”
BackgroundSelf-citationJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 2×
“The cytotoxic activity of C- and P-BiTE antibodies against mutated human CRC cells was assessed by using SW480, HCT116, and HT-29 lines, which harbor mutations in KRAS or BRAF oncogenes and showed resistance against growth inhibition by cetuximab (19).”
BackgroundMethodAntibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Self-citationDreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348
Self-citationHoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Self-citationBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Self-citationBluemel, C., Hausmann, S., Fluhr, P., Sriskandarajah, M., Stallcup, W. B., Baeuerle, P. A., & Kufer, P. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0844-y · Cited by 205
Self-citation
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 284
Metadata
- Authors
- Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., Schaller, E., Herrmann, I., Wolf, A., Urbig, T., Baeuerle, P. A., & Kufer, P.
- Affiliations
- Micromet, 81477 Munich, Germany; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-06-28
- Volume
- 107
- Issue
- 28
- Pages
- 12605-12610
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2906601
- OpenAlex
- W2059739979
- Cited by
- 166
- References
- 22
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 15 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 15 · 2016: 8 · 2015: 8 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Keywords
- EGFR, colorectal cancer, KRAS mutation, BRAF mutation, cetuximab, xenograft tumor growth inhibition
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Humans, Mutation, Neoplasms, Genes, ras, Risk Factors, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. https://app.cochat.ai/papers/10.1073/pnas.1000976107
- The paper
- Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., Schaller, E., Herrmann, I., Wolf, A., Urbig, T., Baeuerle, P. A., & Kufer, P. (2010). T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1000976107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.